Investigating a new treatment for uveal melanoma using a specific drug.

Who could benefit from this research

What this research studies

This research focuses on developing a new drug called 64B, which targets a specific protein involved in cancer growth, to treat metastatic and high-risk uveal melanoma, the most common eye cancer in adults. The approach involves using 64B in combination with other cancer therapies to enhance its effectiveness while minimizing side effects. The research includes preclinical studies in mice to evaluate how well 64B works in slowing tumor growth and improving survival rates. If successful, this treatment could offer a new option for patients with advanced uveal melanoma.

Why it matters

Where this research is happening

• Oncospherix, INC.
  Atlanta, United States Active

Researchers

• Principal investigator: Offermann, Margaret Kenny — Oncospherix, INC.
• Study coordinator: Offermann, Margaret Kenny

Related research

Other NIH-funded projects on the same topics.

• Dual mRNA therapeutics aimed at liver metastasis from uveal melanoma

  A new approach uses two mRNA-based therapies designed to target liver metastases in adults with uveal melanoma.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11388819

• Targeting serotonin receptors to boost a cancer cell weakness in uveal melanoma

  A small funding project tests whether blocking the serotonin HTR2B receptor can weaken mutant GNAQ/GNA11-driven uveal melanoma cells to help fight metastatic eye cancer.

  NIH research Thomas Jefferson University · Philadelphia, United States · NIH-11440890

• Improving treatment response in uveal melanoma by targeting Syk with new translational models

  A Mayo Clinic team is exploring whether blocking the Syk protein can make uveal melanoma more responsive to PARP inhibitors in patients who have this eye cancer that often spreads.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11358775

• How uveal melanoma cells send signals that help them spread

  This project follows adults with uveal melanoma and tracks signals in eye fluid and blood to find early signs that the cancer may be spreading.

  NIH research Children's Hospital of Los Angeles · Los Angeles, United States · NIH-11343371

• A safe, minimally invasive test to predict uveal melanoma metastasis risk from eye fluid

  A new test using a sample from the eye’s aqueous fluid could predict if uveal melanoma is likely to spread, without needing a risky biopsy.

  NIH research Olmeda Biosciences LLC · San Diego, United States · NIH-11312222

• Targeting stress defenses in eye melanoma that spreads to the liver

  Researchers are working to weaken tumor cells' defenses against oxidative damage so liver metastases from uveal (eye) melanoma in adults become more vulnerable to treatment.

  NIH research Drexel University · Philadelphia, United States · NIH-11298994

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.